Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.51 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637447 | 1.00 | MCHR1 (0.51) | MCHR1FPR1FPR2WDR5MEN1 | |
| SCHEMBL1749130 | 0.85 | MCHR1 (0.54) | MCHR1FPR1FPR2WDR5CSF1R | |
| SCHEMBL1749786 | 0.85 | MCHR1 (0.65) | MCHR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL1749132 | 0.85 | MCHR1 (0.54) | MCHR1FPR1FPR2WDR5CSF1R | |
| SCHEMBL1750121 | 0.80 | MCHR1 (0.76) | MCHR1KMT2A | |
| SCHEMBL1750166 | 0.80 | MCHR1 (0.62) | MCHR1FPR1FPR2MEN1LMNA | |
| SCHEMBL1750191 | 0.78 | MCHR1 (0.55) | MCHR1FPR1FPR2WDR5 | |
| SCHEMBL1750189 | 0.78 | MCHR1 (0.55) | MCHR1FPR1FPR2WDR5 | |
| SCHEMBL12530743 | 0.77 | MCHR1 (0.68) | MCHR1CSF1R | |
| SCHEMBL2636922 | 0.75 | GAA (0.48) | MCHR1FPR1FPR2WDR5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | MCHR1 2068/4885FPR1 586/4885FPR2 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.